The National Institute for Health and Clinical Excellence (Nice), part of the UK’s National Health Service (NHS), has published positive diagnostics guidance on DySIS Medical’s cervical cancer screening product, DySIS colposcopy.

By utilising spectral imaging techniques, DySIS colposcopy maps the condition of a woman’s cervix using various colours to indicate normal and abnormal cells.

DySIS shows the degree of abnormality present and helps clinicians take immediate steps to treat patients and prevent disease progression.

Clinical trials across Europe, involving hospitals in the UK, Netherlands and Greece, have shown DySIS improves sensitivity in detecting early stage cervical cancer.

Recently published results also showed that DySIS helped clinicians identify pre-cancer conditions of cervical cancers in 97% of all cases.

North Staffs Hospital consultant gynaecological oncologist Charles Redman said a good screening programme had helped reduce the incidence of cervical cancer in the UK, but detecting the disease early was still a challenge.

"The DySIS instrument uses hi-tech imaging and provides objective measurements that we can use to substantially improve our sensitivity to detecting the disease before it’s too late," Redman said.

DySIS is a clinically and cost-effective option, compared with standard colposcopy, for examining the uterine cervix in women referred for colposcopy, and should be considered in procurement plans for colposcopy equipment, according to NICE guidance.

DySIS Medical CEO Alastair Atkinson said; "This positive guidance recognises the paradigm shift that DySIS can create – helping clinicians to deliver a higher standard of care at a lower overall cost."

The product has received the CE mark and the US Food and Drugs Administration approval.

Image: DySIS colposcopy maps condition of a woman’s cervix using various colours to indicate normal and abnormal cells. Photo: Courtesy of DySISmedical.